key: cord-0999341-7e2nvvdp
authors: Smilowitz, Nathaniel R.; Jethani, Neil; Chen, Ji; Aphinyanaphongs, Yindalon; Zhang, Ruina; Dogra, Siddhant; Alviar, Carlos L.; Keller, Norma; Razzouk, Louai; Quinones-Camacho, Adriana; Jung, Albert S.; Fishman, Glenn I.; Hochman, Judith S.; Berger, Jeffrey S.
title: Myocardial Injury in Adults Hospitalized With COVID-19
date: 2020-11-05
journal: Circulation
DOI: 10.1161/circulationaha.120.050434
sha: 93c6ebc6dc4bd7d3a0f66c3670ba0447eb065623
doc_id: 999341
cord_uid: 7e2nvvdp

nan

2394 CORRESPONDENCE also more frequent in patients with myocardial injury. When grouped by tertile of the initial cTn concentration, patients with the highest initial cTn concentrations were more likely to have in-hospital mortality and critical illness compared with patients in the lowest tertile of initial cTn (Figure) . Among 1498 COVID-19 patients without myocardial injury at the time of initial assessment, serial cTn

Shown are frequencies and odds of in-hospital mortality and critical illness by tertile of initial cardiac troponin (cTn) concentration (A) and peak cTn concentration (B), and based on the timing of myocardial injury (C). Adjusted odds associated with each tertile of cTn in A and B are compared with COVID-19 patients in the lowest tertile of cTn measured. Odds ratios are adjusted for age, sex, race, body mass index, tobacco use, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, previous myocardial infarction, previous heart failure, atrial fibrillation or malignancy, temperature at presentation, pulse oximetry at presentation, outpatient prescriptions for antiplatelets, statin and β-blocker use, C-reactive protein, creatinine, Ddimer, absolute lymphocyte count, and platelet count.

Circulation. 2020;142:2393-2395. DOI: 10.1161/CIRCULATIONAHA.120.050434

December 15, 2020 2395 CORRESPONDENCE measurements were available in 796 (53%). Among these, 278 developed acute myocardial injury in-hospital that was first detected after a median 3.6 (0.9-7.6) days. Associations between cTn and outcomes were consistent when myocardial injury was present at initial cTn measurement, when new myocardial injury occurred in-hospital ( Figure) , and in patients without prevalent coronary artery disease or chronic kidney disease (data not shown).

In total, 943 patients (43.6%) were diagnosed with myocardial injury based on the peak cTn measured during their COVID-19 hospitalization. Patients with myocardial injury based on the peak cTn had higher in-hospital mortality (39.1% versus 9.7%; P<0.001; aOR 5.20 [95% CI, 3.78-7.53]) and more frequent critical illness (61.0% versus 17.9%; P<0.001; aOR 6.16 [95% CI, 4.67-7.89]) than patients without myocardial injury. Individuals with the highest peak cTn concentrations also had the greatest risk of critical illness and death (Figure) .

We report that nearly one-third of patients hospitalized with COVID-19 had myocardial injury at presentation, and nearly half had injury detected during the course of their hospitalization. Regardless of when it was first detected, myocardial injury was associated with increased odds of mortality and critical illness, with higher cTn measurements associated with worse outcomes. The mechanism of myocardial injury is unknown. 1, 4 Among decedents with COVID-19, megakaryocytes associated with fibrin microthrombi were identified within the cardiac, pulmonary, renal, and hepatic microvasculature. 5 Thus, thrombosis may contribute to multi-organ failure in patients with fatal CO-VID-19 infections and may underlie myocardial injury during the course of disease.

This study was retrospective, observational, and only in-hospital outcomes were recorded. Still, this is the first study to demonstrate robust associations between the magnitude and timing of cTn elevation, measured at presentation and during admission, and subsequent critical illness and mortality. The optimal management of patients with myocardial injury in COVID-19 has not been defined and requires further study.

Data sharing: Identifiable data will not be made available to the public. 

Dr Smilowitz is supported, in part, by the National Heart, Lung, And Blood Institute of the National Institutes of Health (K23HL150315); and reports consulting for Abbott Vascular. Dr Fishman is funded, in part, by the National Heart Lung and Blood Institute of the National Institute of Health (R01HL105983, R01HL142498, and R01HL146107). Dr Berger is funded, in part, by the National Heart and Lung Blood Institute of the National Institute of Health (R01HL139909 and R35HL144993). The other authors report no conflicts.

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Thrombosis in hospitalized patients with COVID-19 in a New York City health system

the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series